ELEV Stock Price, Elevation Oncology, Inc. Quote, Chart

Market Summary

USD3.55-0.30

Market Closed

-7.79%

ELEV Stock Price

View Fullscreen

ELEV RSI Chart

ELEV Valuation

Market Cap

187.3M

Price/Earnings (Trailing)

-4.1

EV/EBITDA

-3.96

Price/Free Cashflow

-3.33

MarketCap/EBT

-4.1

ELEV Price/Earnings (Trailing)

ELEV Profitability

Return on Equity

-83.39%

Return on Assets

-51.3%

Free Cashflow Yield

-29.99%

ELEV Fundamentals

ELEV Earnings

Earnings (TTM)

-45.7M

Earnings Growth (Yr)

58.52%

Earnings Growth (Qtr)

25.73%

Breaking Down ELEV Revenue

Last 7 days

-4.9%

Last 30 days

-24.9%

Last 90 days

27.5%

Trailing 12 Months

46.4%

How does ELEV drawdown profile look like?

ELEV Financial Health

Current Ratio

21.22

Debt/Equity

0.55

Debt/Cashflow

-1.86

ELEV Investor Care

Shares Dilution (1Y)

82.03%

Diluted EPS (TTM)

-1.41

Tracking the Latest Insider Buys and Sells of Elevation Oncology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 16, 2024	ferra joseph j jr	sold (taxes)	-20,953	4.39	-4,773	chief executive officer
Mar 16, 2024	ferra joseph j jr	acquired	-	-	12,562	chief executive officer
Feb 15, 2024	furlong tammy	sold (taxes)	-1,116	2.77	-403	chief financial officer
Feb 15, 2024	furlong tammy	acquired	-	-	1,200	chief financial officer
Dec 16, 2023	ferra joseph j jr	sold (taxes)	-2,434	0.51	-4,773	chief executive officer
Dec 16, 2023	ferra joseph j jr	acquired	-	-	12,563	chief executive officer
Sep 16, 2023	ferra joseph j jr	sold (taxes)	-3,474	0.728	-4,773	chief executive officer
Sep 16, 2023	ferra joseph j jr	acquired	-	-	12,562	chief executive officer
Sep 01, 2023	clackson timothy p	gifted	-	-	-15,777	-
Jun 16, 2023	ferra joseph j jr	sold (taxes)	-7,016	1.47	-4,773	interim ceo & cfo

Which funds bought or sold ELEV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	new	-	83,000	83,000	-%
Apr 15, 2024	Palumbo Wealth Management LLC	new	-	91,022	91,022	0.04%
Mar 11, 2024	VANGUARD GROUP INC	added	9.48	-79,894	628,959	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-37,025	-	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-12,000	-	-%
Feb 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	unchanged	-	-113,040	483,300	0.08%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-1.38	-403,365	1,605,780	-%
Feb 14, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-8.31	-680,899	1,969,500	0.18%
Feb 14, 2024	CAXTON CORP	sold off	-100	-14,453	-	-%
Feb 14, 2024	DAFNA Capital Management LLC	unchanged	-	-56,520	241,650	0.06%

Are Funds Buying or Selling ELEV?

Are funds buying ELEV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ELEV

No. of Funds

Unveiling Elevation Oncology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	frazier life sciences public fund, l.p.	3.1%	1,486,390	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	4.0%	1,784,169	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	7.5%	3,344,177	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	9.4%	4,040,000	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	tang capital partners lp	9.99%	4,300,454	SC 13G/A
Feb 14, 2024	orbimed advisors llc	6.8%	3e+06	SC 13G
Feb 07, 2024	exoduspoint capital management, lp	0.1%	50,000	SC 13G/A
Feb 06, 2024	aisling capital iv, lp	6.8%	2,878,296	SC 13G/A
Jan 31, 2024	integrated core strategies (us) llc	7.0%	2,957,348	SC 13G/A

Recent SEC filings of Elevation Oncology, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 09, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 06, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	S-8	Employee Benefits Plan
Mar 04, 2024	3	Insider Trading

Peers (Alternatives to Elevation Oncology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Elevation Oncology, Inc. News

Latest updates

Elevation Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-10.9%	89.00	100	110	77.00	94.00	111	124	134	149	159	159	81.00
Current Assets	-11.0%	88.00	99.00	109	76.00	93.00	110	124	134	149	158	159	81.00
Cash Equivalents	-10.2%	49.00	55.00	106	56.00	46.00	53.00	54.00	53.00	146	155	158	79.00
Net PPE	-13.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-8.7%	34.00	38.00	38.00	43.00	45.00	44.00	19.00	10.00	9.00	9.00	4.00	7.00
Current Liabilities	-45.5%	4.00	8.00	8.00	14.00	16.00	15.00	19.00	10.00	9.00	9.00	4.00	7.00
Long Term Debt	0.6%	30.00	30.00	30.00	30.00	29.00	29.00	-	-	-	-	-	-
LT Debt, Non Current	0.6%	30.00	30.00	30.00	30.00	29.00	29.00	-	-	-	-	-	-
Shareholder's Equity	-12.2%	55.00	62.00	72.00	34.00	49.00	67.00	105	124	141	150	155	-
Retained Earnings	-4.2%	-196	-188	-177	-167	-150	-131	-92.40	-72.46	-55.19	-45.56	-33.30	-23.15
Additional Paid-In Capital	0.1%	251	251	250	201	199	199	197	197	196	195	189	0.00
Shares Outstanding	0.0%	42.00	42.00	42.00	24.00	23.00	23.00	23.00	23.00	23.00	23.00	-	1.00
Float	-	-	-	53.00	-	-	-	22.00	-	-	-	211	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	8.8%	-12,181	-13,357	-13,811	-16,831	-17,849	-44,183	-9,427	-14,024	-8,914	-7,904	-3,872	-9,477	-	-	-
Share Based Compensation	-66.3%	284	843	744	1,464	859	883	837	627	689	659	158	65.00	-	-	-
Cashflow From Investing	117.2%	6,560	-38,117	16,500	26,600	11,181	13,366	10,326	-79,271	-	-	-	-	-	-	-
Cashflow From Financing	-107.4%	-2.00	27.00	47,734	216	-4.00	29,524	-25.00	19.00	-	5,085	91,977	-11.00	-	-	-
Buy Backs	-33.3%	2.00	3.00	7.00	12.00	4.00	6.00	25.00	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ELEV Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 25,434	$ 78,717
General and administrative	14,904	15,832
Restructuring charges	5,107	0
Total operating expenses	45,445	94,549
Loss from operations	(45,445)	(94,549)
Other expense, net	(229)	(506)
Loss before income taxes	(45,674)	(95,055)
Income tax expense	30	25
Net loss	$ (45,704)	$ (95,080)
Net Loss Per Share
Net loss per share, basic (in dollars per share)	$ (1.34)	$ (4.09)
Net loss per share, diluted (in dollars per share)	$ (1.34)	$ (4.09)
Weighted average common shares outstanding, basic (in shares)	34,077,675	23,267,120
Weighted average common shares outstanding, diluted (in shares)	34,077,675	23,267,120
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	$ 170	$ (161)
Total other comprehensive income (loss)	170	(161)
Total comprehensive loss	$ (45,534)	$ (95,241)

ELEV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 49,255	$ 45,917
Marketable securities, available for sale	33,852	44,363
Prepaid expenses and other current assets	4,857	2,697
Total current assets	87,964	92,977
Property and equipment, net	59	98
Other non-current assets	1,068	1,086
Total assets	89,091	94,161
Current liabilities:
Accounts payable	507	6,362
Accrued expenses	3,638	9,330
Total current liabilities	4,145	15,692
Non-current liabilities:
Long-term debt, net of discount	30,137	29,435
Restricted stock repurchase liability	0	2
Total liabilities	34,282	45,129
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and 2022, respectively; no shares issued or outstanding as of December 31, 2023 and 2022, respectively	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 42,470,264 and 23,345,115 shares issued as of December 31, 2023 and 2022, respectively; 42,422,531 and 23,312,529 shares outstanding as of December 31, 2023 and 2022, respectively	4	2
Additional paid-in capital	250,825	199,492
Accumulated other comprehensive income (loss)	9	(161)
Treasury stock, 47,733 and 28,641 shares as of December 31, 2023 and 2022, respectively, at cost	(59)	(35)
Accumulated deficit	(195,970)	(150,266)
Total stockholders' equity	54,809	49,032
Total liabilities and stockholders' equity	$ 89,091	$ 94,161

About Elevation Oncology, Inc.

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

CEO	Mr. Joseph J. Ferra Jr.
WEBSITE	https://elevationoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	33

Elevation Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Elevation Oncology, Inc.? What does ELEV stand for in stocks?

ELEV is the stock ticker symbol of Elevation Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Elevation Oncology, Inc. (ELEV)?

As of Mon Apr 29 2024, market cap of Elevation Oncology, Inc. is 187.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELEV stock?

You can check ELEV's fair value in chart for subscribers.

What is the fair value of ELEV stock?

You can check ELEV's fair value in chart for subscribers. The fair value of Elevation Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Elevation Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELEV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Elevation Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELEV is over valued or under valued. Whether Elevation Oncology, Inc. is cheap or expensive depends on the assumptions which impact Elevation Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELEV.

What is 5 year return on Elevation Oncology, Inc.'s stock?

In the past 10 years, Elevation Oncology, Inc. has provided 0.623 (multiply by 100 for percentage) rate of return.